Elevated proinflammatory cytokines combined with low peripheral blood counts early after CD19 CAR-T cell infusion correlate with poor treatment response and severe toxicity in relapsed/refractory B-ALL, highlighting inflammation as a key modifiable factor for improving outcomes.